Our fourth quarter edition features leading insights from subject matter experts covering a range of topics, with a focus on innovations driving the future of healthcare, including solutions to the COVID-19 pandemic. In this issue, leaders from all facets of the pharmaceutical industry discuss their approach to developing and distributing COVID-19 vaccines globally, enabling innovation, facilitating decentralized clinical trials, stem cell technology, and ways to communicate and conduct marketing virtually during the pandemic.
Rentschler Biopharma highlights their focus on clients' COVID-19 programs, including manufacturing support for the BioNTech/Pfizer mRNA vaccine.
Nigel Walker discusses delivering vaccines during a pandemic.
Ryan MacDonald, Senior Engineer, Manufacturing Quality Sciences at Avid Bioservices, discusses the company's adoption of single-use technology.
In our Q4 cover story, Rentschler Biopharma SE's CEO Frank Mathias, Ph.D., explains how the company develops best-fit solutions for complex client challenges to face the future of biopharmaceuticals.
Rose Blackburne M.D., John Manns, Tim Rich, and Michael Noss, M.D. of PPD discuss how decentralized clinical trials strategies enable dermatological clinical trials.
Polyvinyl alcohol excipients can optimize API solubility in hot melt extrusion formulations, explain Daniel J. Price, Ph.D., and Thomas Kipping, Ph.D. of MilliporeSigma.
Graham Brearley of Catalent and Jared Davis, formerly of Arcturus Therapeutics, discuss the partnership between the companies to manufacture a COVID-19 mRNA vaccine.
PCI Pharma Services' Director of Digital Products Morgan Brandt explains how PCI's digital transformation and the launch of pci | bridge provides customers with real-time data access to comprehensive supply chain information.
A panel of experts from Corning Life Sciences explain how organoids and other emerging technologies are enabling personalized medicine.
Melanie Cerullo and Susan Surabian highlight Arranta Bio's commitment to corporate social responsiblity and diversity.
Jessica Shea explains how MilliporeSigma's Emprove Program helps aid customers in the evaluation of extractables and leachables.
In this Q&A, Justin Kadis of Federal Equipment Company explains how the company responded to the challenges of COVID-19 by pioneering virtual trade shows.
Pierre Luzeau, Chief Executive Officer of Seqens, explains how the company is investing and growing to meet the challenges of the future of small molecule manufacturing.
Rizwan Chaudhrey, founder and CEO of RSK Life Science Media, explores the importance of social media in digital marketing.
Aaron Styles, Vice President of Environmental Systems Corporation explains how modular construction models can increase efficiency and reduce costs of construction.
Andrew T. Boyle, Co-president of Boyle Transportation, explains the challenges ahead in the distribution of a COVID-19 vaccine.
Mobile research nursing is critical to the success of decentralized clinical trials during the pandemic, explains Jules Moritz, COO of Illingworth Research Group Ltd.
The Pharma's Almanac team looks at how wearables may transform clinical trials and beyond.
Our editors explore the range of potential indications and applications for wearable technologies.
The Pharma's Almanac team looks at how wearables may transform clinical trials and beyond.
Jyothi Swamy, Ph.D., and Elizabeth McKee describe how MilliporeSigma has established itself as a CDMO supporting all aspects of ADC programs.
New technology is bringing Sanger DNA sequencing to the benchtop, details Gabriela Saldanha of Promega Corporation.
Jonathan Javitt, M.D., discusses how NeuroRx has shifted focus from a psychiatric pipeline to pursue a promising therapeutic for COVID-19.
Nice Insight's Emilie Branch explores how AVM Biotechnology is approaching immun-onocology with a novel formulation of dexamethasone that mobilizes NKT cells.
The COVID-19 pandemic has exposed existing weaknesses in international supply chains, explains Haig Armaghanian, Founder and CEO of Haig Barrett.
Allogeneic, undifferentiated pluripotent stem cells have the potential to transform the treatment of neurodegenerative diseases, explains Sandy Solmon of Celavie Biosciences.
Elastic computing has considerable potential to enable single-cell omics and analytics, according to Paradigm4's Marilyn Matz and Zachary Pitluk, Ph.D.
Deborah A. Graham of Avara Pharmaceutical Services explains how Avara supports clients through specialized OSD services.
The development of AAV platform technologies will be key to increasing efficiency and unlocking the potential of gene therapies, explains Felix Hsu, CCO of WuXi Advanced Therapies.
Increasing the Efficiency of Drug Development with Preclinical Testing Using Human Intestinal Stem Cells, Altis Biosystems, Ron Laethem
Larry Kenyon explains how Outlook Therapeutics is addressing retinal diseases via the first ophthalmic formulation of bevacizumab.
TriRx Pharmaceutical Services' CEO Tim Tyson discusses the company's expansion into animal health development and manufacturing.
The That's Nice road team prepares for their pan-European journey to explore the future of healthcare.
Day 0: England
Day 1: England and Wales
Day 2: Wales, Ireland, and Northern Ireland
Day 3: Scotland and England
Day 4: France and Belgium
Day 5: Belgium and the Netherlands
Day 6: The Netherlands, Germany, and Denmark
Day 7: Denmark and Sweden
Day 8: Sweden and Finland
Day 9: Finland, Estonia and Latvia
Day 10: Latvia and Lithuania
Day 11: Lithuania and Poland
Day 12: Poland and the Czech Republic
Day 13: The Czech Republic and Slovakia
Day 14: Slovakia and Hungary
Day 15: Hungary and Croatia
Day 16: Croatia, Slovenia, and Austria
Day 17: Austria
Day 18: Austria, Germany, Liechtenstein, and Switzerland
Day 19: Switzerland and Italy
Day 20: Italy
Day 21: Italy, Monaco, and France
Day 22: France and Luxembourg
Day 23: France and Luxembourg
Day 24: France
Day 25: France and England
SanaClis assesses the pandemic's impacts on clinical trials models.
Polpharma Biologics sees the acceleration of development timelines as a key outcome of the pandemic.
Yourway discusses trends changing the clinical trial landscape and how the company is investing to support them.
Inceptor Bio highlights disruptive technologies on the horizon and the long-term impacts of COVID-19.
Pii explore how the intersection of scientific innovation and accelerated timelines will drive the future of pharma.
Federal Equipment Company explores how technological innovations are keeping the used equipment market viable in pandemic times.
Arranta Bio highlights technological innovations needed to realize the potential of microbiome therapies.
SGD Pharma discusses the impact of the COVID-19 pandemic on the glass pharmaceutical packaging market.
AES Clean Technology explore the future of cleanrooms and contamination-control technologies.
Avara Pharmaceutical Services discusses how they are investing and building relationships to meet customer needs beyond the pandemic.
Globyz Biopharma Services looks forward to supporting clinical trials in a more virtual future.
SPI Pharma emphasizes the importance of innovations focused on the patient experience going forward.
Dynamk Capital is focused on the future as they monitor potentially disruptive innovations.
TriRx Pharmaceutical Services discusses trends shaping the future of pharma and the critical role for CDMOs.
Evolve Biologics believes that their PlasmaCap EBA technology will transform the future of the plasma proteins market.
ECRI explains how an increased emphasis on patient safety will continue to transform the industry.
Altis Biosystems discusses the potentially transformative role of in vitro tissue models in preclinical testing.
A panel of SMEs discusses the lasting impacts of the COVID-19 pandemic.
Industry experts explore what it takes to make an organization "crisis-proof."